{
    "clinical_study": {
        "@rank": "52114", 
        "arm_group": [
            {
                "arm_group_label": "Renal denervation + medical therapy", 
                "arm_group_type": "Experimental", 
                "description": "Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure"
            }, 
            {
                "arm_group_label": "Medical therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Standard optimized medical therapy for diastolic heart failure"
            }
        ], 
        "brief_summary": {
            "textblock": "It is a randomized prospective controlled study of transcatheter renal denervation in\n      patients with Heart Failure With Normal LV Ejection Fraction. The purpose of the study is to\n      evaluate the safety and effectiveness of renal denervation in patients with  Heart Failure\n      With Normal LV Ejection Fraction, due to reduction in renal and systemic sympathetic\n      activity."
        }, 
        "brief_title": "Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction", 
        "condition": [
            "Heart Failure, Diastolic", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Hypertension", 
                "Heart Failure, Diastolic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hypertension treated with at least 2 antihypertensive drugs;\n\n          -  Heart failure with a normal LV ejection fraction;\n\n          -  Left Ventricular Hypertrophy (LV mass index > 96 g/m2 in women and > 116 g/m2 in\n             men);\n\n          -  \u2265 18 years of age;\n\n        Exclusion Criteria:\n\n          -  Known secondary cause of hypertension\n\n          -  Uncontrolled blood pressure (\u2265 180x110mmHg)\n\n          -  Unsuitable anatomy of renal arteries, renal stenosis or previous treatment with\n             balloon or stent\n\n          -  Advanced renal insufficiency (estimated glomerular filtration rate (GFR) < 30\n             ml/min/1.73 square meters)\n\n          -  Diabetes Mellitus type 1\n\n          -  Acute coronary syndrome or a cerebrovascular accident in the last 6 months\n\n          -  Known other cause of respiratory dysfunction\n\n          -  Previous LV systolic dysfunction (LVEF < 50%)\n\n          -  Restrictive cardiomyopathy or Hypertrophic cardiomyopathy\n\n          -  Significant valvar dysfunction\n\n          -  Atrial flutter or atrial fibrillation\n\n          -  Use of the oral anticoagulants\n\n          -  Drug and Alcohol dependence"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115230", 
            "org_study_id": "IncorRDN-ICFEN"
        }, 
        "intervention": {
            "arm_group_label": "Renal denervation + medical therapy", 
            "description": "Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure", 
            "intervention_name": "Renal denervation + medical therapy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart Failure", 
            "Heart Failure, Diastolic", 
            "Hypertension", 
            "Renal Denervation", 
            "Irrigated Radiofrequency Catheter"
        ], 
        "lastchanged_date": "April 13, 2014", 
        "location": {
            "contact": {
                "email": "patricia.pereira@incor.usp.br", 
                "last_name": "Patricia Pereira", 
                "phone": "+55 11 2661-5368"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "05403-000"
                }, 
                "name": "Heart Institute - InCor. University of Sao Paulo Medical School"
            }, 
            "investigator": {
                "last_name": "Pedro Lemos, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter", 
        "overall_official": {
            "affiliation": "Heart Institute - InCor. University of Sao Paulo Medical School", 
            "last_name": "Pedro A Lemos, MD PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Brazil: Ethics Committee", 
                "Brazil: National Committee of Ethics in Research"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Efficacy: Change from baseline E/E' on echocardiography at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months after treatment"
            }, 
            {
                "measure": "Safety: Composite of death, myocardial infarction, cerebrovascular event, need of intervention on renal arteries and renal function impairment (decrease in estimated GFR > 30% from baseline)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115230"
        }, 
        "responsible_party": {
            "investigator_affiliation": "InCor Heart Institute", 
            "investigator_full_name": "Pedro A. Lemos", 
            "investigator_title": "Pedro A. Lemos, Professor of Medicine, InCor Heart Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline E/E' on echocardiography at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change of office blood pressure and ambulatory blood pressure monitoring (ABPM)  between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in any echocardiographic diastolic parameter between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in 6 min walking distance between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in quality of life (Minnesota Living with Heart Failure Questionnaire) between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in serum B-type natriuretic peptide (BNP) between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in peripheral sympathetic activity measured by microneurography between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in non-invasive hemodynamic parameters provided by Finometer between baseline and 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Change in renal function (GFR, albuminury and 24h urinary Na excretion) between baseline and 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "InCor Heart Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InCor Heart Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}